Empowering Venture Capital Associates
In this episode of the NextGenVC podcast, hosts Jen Fang and Mike Hostetler are joined by Chris Garabedian, founder of Xontogeny and biopharma veteran, to discuss the transformative impact of early-stage biotech investment. Chris shares his journey from biotech corporate leadership to venture capital, emphasizing the importance of thoughtful drug development and the value of nurturing early-stage companies. He explains the inception of Xontogeny, its collaboration with Perceptive Advisors, and the unique venture incubation model they follow. Chris also highlights the essential qualities for success in biotech investing and offers insights for budding entrepreneurs and potential VCs alike.
Mike is a partner in the San Francisco (SoMa) and San Diego offices of Wilson Sonsini Goodrich & Rosati. He has provided strategic intellectual property counseling to hundreds growth enterprises in the pharmaceutical and biotechnology industries, both venture-backed and public companies. His expertise includes patent strategy, prosecution, and diligence (both buy and sell side) for venture financings, public offerings, mergers and acquisitions.
Jennifer is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. She helps innovative startups grow into successful enterprises by providing counsel to the founders, management teams and boards and by handling the legal and strategic business issues and transactions that arise at each stage. She is a member of the National Venture Capital Association (NVCA) General Counsel Advisory Board and is a frequent speaker.
Powered by LaunchBio with generous support from Wilson Sonsini
